NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, has posted fourth quarter total revenue of $2.3 million, according to a company news release.
Other highlights from NeurogesX's 4Q include a 54 percent increase in hospital purchases of its Qutenza (capsaicin) 8 percent patch. Qutenza is a localized dermal delivery system containing prescription-strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia.
The company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.
Read the news release about NeurogesX's 4Q financial results.
Related Articles on Pain Management:
Kentucky AG Office Says County Governments Cannot Ban Pain Clinics
Opioid Pain Medications Drive "Epidemic" of Unintentional Drug Overdose Deaths
North Carolina Pain Management Physician Pleads Guilty to Healthcare Fraud